Author:
Gantait Kripasindhu,Chattopadhyay Debraj,Das Surajit
Publisher
Jaypee Brothers Medical Publishing
Reference11 articles.
1. 1. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76(6):960–977. DOI: 10.1136/annrheumdis- 2016-210715.
2. 2. Lertnawapan R, Chonprasertsuk S, Siramolpiwat S. Association between cumulative methotrexate dose, noninvasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate. Int J Rheum Dis 2019;22(2):214–221. DOI: 10.1111/1756-185X.13442.
3. 3. Mangoni AA, Zinellu A, Sotgia S, et al. Protective effects of methotrexate against proatherosclerotic cytokines: A review of the evidence. Mediators Inflamm 2017;2017:9632846. DOI: 10.1155/2017/9632846.
4. 4. Kremer JM, Alarcòn GS, Lightfoot RW, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37(3):316–328. DOI: 10.1002/art.1780370304.
5. 5. Whiting-O'Keefe QE, Fye KH, Sack KD, et al. Methotrexate and histologic hepatic abnormalities: A meta-analysis. Am J Med 1991;90(6):711–716. PMID: 1828327.